论文部分内容阅读
目的评价艾帕培南对小鼠大肠埃希菌泌尿道上行性感染的体内疗效。方法通过泌尿道钝针头插管法,向小鼠膀胱内注入0.05m L浓度为1010CFU/m L的大肠埃希菌9612菌液,建立小鼠泌尿道感染模型。于感染后6、24和30h皮下给药,感染后48h处死动物,取肾剖面盖印和研磨计数,评价艾帕培南的疗效,并与对照药美罗培南、厄他培南进行比较。结果艾帕培南对小鼠的大肠埃希菌9612泌尿道上行性感染具有较好疗效,给药后0.5、2和8 mg/kg剂量组小鼠肾组织匀浆菌落计数明显低于对照组(P<0.01),0.125、0.5、2和8mg/kg剂量组肾剖面盖印结果均与对照组有显著差异(P<0.01)。艾帕培南与相同剂量组美罗培南、厄他培南相比,肾组织匀浆菌落计数和肾剖面盖印结果均无显著性差异(P>0.05)。结论艾帕培南对小鼠泌尿道大肠埃希菌9612上行性感染具有较好疗效,体内抗菌活性与美罗培南、厄他培南相近。
Objective To evaluate the in vivo efficacy of ipamipenem against esophageal Urethritis in mice. Methods The mouse urinary tract infection model was established by injecting 0.05m L of Escherichia coli 9612 strain with a concentration of 1010 CFU / mL through urinary blunt needle cannulation. The animals were sacrificed at 6, 24 and 30 hours after infection, animals were sacrificed at 48 hours after infection, the sections of the kidney were stamped and grinded to evaluate the efficacy of iperidam and compare with the control drugs Meropenem and Ertapenem. Results Ipapenem had a good effect on urinary tract infection of Escherichia coli 9612 in mice, and the colony counts of renal homogenates in 0.5, 2 and 8 mg / kg dose groups were significantly lower than those in control group (P <0.01). The results of renal section imprinting in 0.125,0.5,2 and 8mg / kg dose groups were significantly different from those in control group (P <0.01). Compared with meropenem and ertapenem in the same dose group, there was no significant difference (P> 0.05) between the count of kidney homogenate and the result of renal section stamped. Conclusion Ipapenem has good effect on urinary tract Escherichia coli 9612 infection in mice, and its antibacterial activity in vivo is similar to that of Meropenem and Ertapenem.